

Nilotinib

✓ 5 mg

Orders ■ 877-616-CELL (2355)
orders@cellsignal.com


Support ■ 877-678-TECH (8324)
info@cellsignal.com

Web ■ www.cellsignal.com

rev. 06/15/18

For Research Use Only. Not For Use In Diagnostic Procedures.

Background: Nilotinib (AMN-107) is a novel tyrosine kinase inhibitor that potently inhibits Bcr-Abl. Nilotinib is more effective than imatinib at decreasing the proliferation and viability in cells expressing wild-type Bcr-Abl and is active against many imatinib-resistant Bcr-Abl mutants, with the exception of T315I (1-4). Nilotinib has been shown to inhibit Abl activity in cells expressing wild-type Abl and imatinib-resistant mutant Abl, with ~20-fold greater potency than imatinib. Nilotinib is similarly effective at inhibiting Abl autophosphorylation (3). Research studies have demonstrated that nilotinib treatment of Bcr-Abl-expressing K-562 cells attenuates Stat5 and CrkL phosphorylation, decreases Bcl-xL and c-Myc expression, induces p27 and Bim expression, and induces PARP cleavage. Many of these effects are enhanced by cotreatment with the histone deacetylase inhibitor LBH589 (5).

Molecular Formula: C₂₈H₂₂F₃N₃O**Molecular Weight:** 529.52 g/mol


Solubility: Soluble in DMSO at 50 mg/ml; very poorly soluble in ethanol and water with maximum solubility in water at ~10-20 µM.

Purity: >99%

Directions for Use: Nilotinib is supplied as a lyophilized powder. For a 5 mM stock, reconstitute the 5 mg in 1.89 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 10-1000 nM for 2-72 hr.

Background References:

- (1) Weisberg, E. et al. (2006) *Br J Cancer* 94, 1765-9.
- (2) Golemovic, M. et al. (2005) *Clin Cancer Res* 11, 4941-7.
- (3) O'Hare, T. et al. (2005) *Cancer Res* 65, 4500-5.
- (4) Weisberg, E. et al. (2005) *Cancer Cell* 7, 129-41.
- (5) Fiskus, W. et al. (2006) *Blood* 108, 645-52.



Western blot analysis of extracts from K562 cells untreated (-) or treated with Nilotinib (+) at 1 µM for 24 hours, using Phospho-CrkL (Tyr207) Antibody #3181 (upper), CrkL (D4G7G) Rabbit mAb #38710 (middle) and β-Actin (D6A8) Rabbit mAb #8457 (lower).

Storage: Store lyophilized or in solution at -20°C, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.